Cronos Group (NASDAQ:CRON – Get Free Report) and Urogen Pharma (NASDAQ:URGN – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, institutional ownership and valuation.
Analyst Ratings
This is a summary of current ratings and price targets for Cronos Group and Urogen Pharma, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cronos Group | 0 | 2 | 3 | 0 | 2.60 |
| Urogen Pharma | 1 | 1 | 8 | 0 | 2.70 |
Cronos Group presently has a consensus target price of $2.30, suggesting a potential downside of 28.35%. Urogen Pharma has a consensus target price of $52.38, suggesting a potential upside of 51.55%. Given Urogen Pharma’s stronger consensus rating and higher possible upside, analysts clearly believe Urogen Pharma is more favorable than Cronos Group.
Risk and Volatility
Cronos Group has a beta of 0.9, suggesting that its share price is 10% less volatile than the S&P 500. Comparatively, Urogen Pharma has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500.
Profitability
This table compares Cronos Group and Urogen Pharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cronos Group | 39.08% | 4.85% | 4.62% |
| Urogen Pharma | -51.73% | N/A | -43.79% |
Earnings and Valuation
This table compares Cronos Group and Urogen Pharma”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cronos Group | $146.59 million | 8.07 | -$9.45 million | $0.20 | 16.05 |
| Urogen Pharma | $109.79 million | 15.39 | -$153.49 million | ($1.98) | -17.45 |
Cronos Group has higher revenue and earnings than Urogen Pharma. Urogen Pharma is trading at a lower price-to-earnings ratio than Cronos Group, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
8.7% of Cronos Group shares are held by institutional investors. Comparatively, 91.3% of Urogen Pharma shares are held by institutional investors. 7.8% of Cronos Group shares are held by company insiders. Comparatively, 4.8% of Urogen Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Cronos Group beats Urogen Pharma on 8 of the 14 factors compared between the two stocks.
About Cronos Group
Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.
About Urogen Pharma
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Receive News & Ratings for Cronos Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cronos Group and related companies with MarketBeat.com's FREE daily email newsletter.
